View Selank Nasal Spray In SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), the largest trial in the obesity population (N = 2,539 over 72 weeks): Psychiatric adverse events overall: 5 to 7% across treatment arms, similar to placebo Anxiety specifically: not flagged as a notable adverse event Depression: not flagged as a notable adverse event Suicidal ideation: rare, not significantly different from placebo The most common adverse events in the trials were gastrointestinal: nausea, diarrhea, vomiting, constipation
Weiss N, Zhang YY, Heydrick S, Bierl C, Loscalzo J
Understand that maintaining weight loss likely means maintaining 40-60% of loss, not all of it The Structured Transition Protocol If youre attempting this path, heres the evidence-based approach that gives you the best chance: Month 1-2: Gradual Taper Week 1-2: Reduce dose by 25% Week 3-4: Reduce to 50% of original dose Week 5-6: Reduce to 25% of original dose Week 7-8: Discontinue completely Rationale: Sudden cessation causes abrupt return of hunger signals
The rate of onset varies significantly between individuals
Semaglutide slows gastric emptying, which could theoretically delay the absorption of oral medications